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Objectives: In cost-utility analyses (CUAs) it is common to estimate the utility 
of patients while on treatment or when experiencing comorbidities by adjusting 
their baseline utility with the treatment/comorbidity-related utility decrement. 
This study assessed the impact of adjusting patients’ baseline utility with additive 
versus multiplicative utility decrements on the lifetime quality-adjusted life years 
(QALYs) in CUAs for two chronic illnesses. MethOds: Two Markov models were 
developed. In the first model, utility during treatment was obtained by adjust-
ing the baseline utility with the treatment-related utility decrement; treatment 
was given for one year. In the second model, utilities with comorbidities were 
obtained from external sources and were combined with the health state utilities 
by considering the lowest value. In both models, the response of the multiplicative, 
additive and the combined approach was investigated by comparing the number 
of QALYs gained over a lifetime. Results: In the first model, as treatment was 
only given during the first year, the impact on the number of QALYs gained over 
a lifetime was minimal. Thus, a similar incremental cost-effectiveness ratio per 
QALY (ICER/QALY) was obtained with all the approaches. In contrast, for the second 
model, the number of QALYs gained over a lifetime between the approaches was 
significantly different. This is because comorbidities were experienced during a 
longer period of time. Consequently, the difference in ICER/QALY was also substan-
tial. cOnclusiOns: When developing CUA, either a multiplicative or combined, 
rather than additive, approach should be used to calculate the utility of patients 
during treatment or with comorbidities, using utility decrements, if consider-
able uncertainty is present in the baseline utility. However, if QALYs gained with 
treatment or with comorbidities represent only a small fraction of the overall 
QALYs gained, the difference between the approaches is not expected to have a 
significant impact on the results.
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Objectives: The European Union’s (EU) 2011 Directive on cross-border health care 
establishes the right of EU citizens to receive treatment abroad and be reimbursed 
in their home country. While the focus has been on patient mobility and access, it 
may also facilitate international outsourcing of services between countries. This 
research examines the methodological challenges in evaluating the costs and 
consequences of cross-border service provision. MethOds: Using the example 
of deep brain stimulation (DBS) treatment in Ireland, we conducted an economic 
analysis of the provision of cross-border services from the perspective of the public 
health system. This included an analysis of clinical and cost-effectiveness, ethical 
and societal implications and the challenges of integrating care between sepa-
rate health systems. Results: Accurate modelling of the provision of a new or 
expanded service serves as the basis for evaluating costs, impact on patients and 
potential gaps in continuity of care. Cost minimisation analysis may be appropriate 
under some circumstances, with due regard to the importance of patient selec-
tion and follow up. Cross-border services may have significant implications for 
equity of access, with potential negative consequences for those most in need of 
treatment. Results of the economic analysis indicate that a national DBS service 
in Ireland would cost an additional € 20,900 per patient over 10 years. The potential 
for anomalies within health systems with a mixture of private and public funders 
is highlighted, with the difference being reduced to € 4,100 per patient in a single 
payer scenario. cOnclusiOns: Health care funding structures can impact signifi-
cantly on the cost-effectiveness of cross-border services, even when differences in 
the actual cost of care are minimal. Given the externalities involved, analysis from 
the payer perspective may be too narrow for the economic evaluation of routine 
cross-border provision of elective services.
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Objectives: Accurate measurement of resource use is required for economic 
evaluations alongside clinical trials. Patient-completed questionnaires are com-
monly employed as a means of collecting data; however, concerns over data qual-
ity persist, and there is little certainty about best practice. This review collates the 
evidence concerning the validity and reliability of resource-use measures based 
on patient recall with the aim of aiding health economists in developing better 
measures. MethOds: A search strategy incorporating terms covering health care 
resources, utilisation, patient-reported measures and validation/reliability con-
cepts was applied to the MEDLINE, EMBASE and PsycINFO bibliographic databases. 
Studies were included if they reported original research to inform costing studies, 
and were about patient or proxy self-reports of direct health care-related resource 
use in which a comparator (to assess validity or reliability) was specified. Studies 
were excluded if they were not in English or if they assessed general population 
surveys. Reference and citation lists of included studies were hand searched to 
identify additional studies. Data on study and population characteristics, type of 
instrument, recall period and sample size were extracted. Results and conclusions 
concerning the validity and reliability of reports of types of resource use consumed 
(e.g.medication, inpatient stays) were also extracted. Results: A total of 13,367 
abstracts were identified as potentially relevant through the database searches. 
Following abstract and full-text screening, 60 articles were deemed relevant, with a 
further 9 identified through hand searching. The majority focused on adults (60/69), 
with conventional DMARDs only. The sequence of treatments used after the fail-
ure of first biologic treatment was to be included as part of the cost-effectiveness 
modelling. We therefore built a model to match the treatment pathway for first-line 
biologics and beyond. MethOds: We researched the treatment pathway and exist-
ing cost-effectiveness models in order to create an appropriate model. We rebuilt 
the model used by the technology assessment group in TA195, which considered 
second-line biologics and beyond. We adapted this model to reflect the current 
treatment pathway and consider first line biologics. Results: We created a patient 
simulation model, which generated a cohort of virtual patients and tracked their 
costs and QALYs over the pathway. Patients began treatment with a biologic, and 
could discontinue at month 6 due to an adverse event (AE), in which case they 
switched to a different biologic, with first-line efficacy. Patients who did not have 
an AE discontinued at month 6 if their DAS 28 improvement was insufficient. After 
discontinuation at month 6, or later, patients next received rituximab, unless con-
traindicated. If rituximab was contraindicated, or the patient had an AE by month 
6, they moved onto another biologic treatment, after which they received a DMARD 
treatment sequence (including palliative care). Patients who had insufficient DAS28 
response on rituximab at month 6 switched to tocilizumab (unless received previ-
ously), after which they received the DMARD sequence. Patients who had sufficient 
DAS28 improvement with rituximab remained on rituximab long-term, until they 
received the DMARD treatment sequence. Patients could exit the model at any point 
if they died. cOnclusiOns: We used robust methodology and clinical rationale to 
assess the cost-effectiveness of licenced treatments reflected across NICE’s recom-
mended treatment pathway for RA.
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Objectives: In 2013, NCPE assessed the cost-effectiveness of subcutaneous (SC) 
abatacept as a first line biologic for the treatment of rheumatoid arthritis (RA), 
compared to existing biologics. It was necessary to consider the treatment path-
way beyond first line biologics. We therefore built a model to match the treatment 
pathway for first line biologics and beyond. MethOds: We used our individual 
patient sampling model for England and Wales as a starting point to create a model 
which considers biologic cycling, to match the treatment pathway in Ireland. We 
differentiated between the efficacy of a biologic at first line, and at second line 
or later. Results: We created a model which could be used to calculate the cost-
effectiveness of biologics for the treatment of RA in Ireland. Patients first received 
treatment with SC abatacept, intravenous abatacept, adalimumab, etanercept, 
infliximab, certolizumab pegol or golimumab. If they experienced an adverse event 
(AE) on that treatment within 6 months, they switched to another biologic at first 
line efficacy. If not, their response to treatment was tested using the DAS28: if this 
improved by 1.2 or more, their time on treatment was sampled from a Weibull 
distribution, otherwise they discontinued at month 6. The patient then moved onto 
a randomly sampled second line biologic, which was either one of the first line bio-
logics or rituximab. The time on second line biologic was sampled from a Weibull 
distribution, and then the patient moved onto a third line biologics (second line 
biologics and tocilizumab). The patient cycled through the biologics until they died, 
or had received all 8 treatments. After 8 biologics, remaining patients received 
leflunomide, cyclosporin, azathioprine and palliative care. cOnclusiOns: We 
used robust methodology and clinical rationale to model the treatment pathway of 
biologics for RA in Ireland and facilitated cost-effectiveness comparison between 
first line biologics.
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Objectives: To perform a systematic literature review of economic evidence 
for genotype 1 hepatitis C virus (HCV) treatments and to summarise and assess 
the methods used in recent economic evaluations. MethOds: Multiple data-
bases were searched to identify economic evaluations in patients with genotype 
1 HCV. Detailed review methods are presented elsewhere. Results: 53 economic 
analyses and 17 Health Technology Assessment (HTA) documents were identified. 
Most economic analyses were performed using lifetime horizon Markov models, all 
for interferon-containing regimens. Most were performed in the United Kingdom 
(UK) (n = 13), United States (n = 13), or Germany (n = 7). Two recent National 
Institute for Health and Care Excellence (NICE) submissions were included: tel-
aprevir triple therapy (with peginterferon plus ribavirin) and boceprevir triple 
therapy, for previously treated and untreated patients. The models used were 
different; however their structures and some inputs were based on previous 
NICE appraisals for peginterferon plus ribavirin. There were a number of limita-
tions found in the included economic evaluations, which may have affected the 
cost-effectiveness outcomes: 1) The models did not adequately capture all health 
benefits and costs in their quality-adjusted life-year calculations; 2) The models 
did not account for the possibility of benefits caused by reduced transmission of 
HCV; 3) The models did not incorporate patient factors that may influence disease 
progression; 4) Modelling of subgroups may have been insufficient, particularly 
as the understanding of patient and viral factors that predict treatment response 
grows; and 5) Some made generalisations for the compensated cirrhosis popula-
tion that were not comparable with the UK population. cOnclusiOns: Recent 
economic models have generally adhered to previous iterations of HCV models and 
have not evolved with our knowledge of the disease. In light of upcoming treat-
ment alternatives, model refinement may be necessary to capture the increasingly 
complex treatment decisions that will be required.
